Biocon Limited · NSE:BIOCON
Biocon — Investor Presentation (December 2022)
40 slides from Biocon's investor presentation, December 2022
Slide 1: Biocon Limited Corporate Presentation
Biocon Limited CORPORATE PRESENTATION December 2022 1
Slide 2: Biocon is a technology-enabled global biopharmaceuticals leader
Biocon is a technology- enabled, future-ready, global biopharmaceuticals leader driven by an unwavering purpose to enhance healthcare worldwide through high quality, affordable therapies that can lower costs, increase access and improve treatment outcomes. 2
Slide 3: Vision and Values
VISION To enhance global healthcare through innovative and affordable biopharmaceuticals for patients, partners and healthcare systems across the globe. VALUES • Integrity & Ethical Behavior • Performance driven Work Culture • Value Creation through Innovation & Differentiation • Quality through Com
Slide 4: The Biocon Manifesto
The Biocon Manifesto accessibility affordability • Use our science, scale and expertise • Focus on the kind of innovation that As a committed to enhance access to essential adds the condition of affordability drugs for patients on the lowest to accessibility stakeholder of the global rung of the eco
Slide 5: Biocon At A Glance
Biocon At A Glance Rs 83,967 mn | $1.1 bn 15,000+ Revenue* Total Employees 50+ 1,300+ cGMP approvals from International Patents regulatory agencies 120+ Ranked 8 Countries where our products are Among Top 10 Global Biotech Employers available by Science magazine *FY22 ended March 31, 2022 5
Slide 6: Our Business Evolution Over The Years
Our Business Evolution Over The Years FY1999 FY2004 FY2009 FY2015 FY2018 FY2022 People Revenue People Revenue Revenue People Revenue People Revenue People Revenue USD 5 USD 85 People USD 484 USD 667 USD 1.1 250 700+ 3,500+ USD 184 7,500+ 10,000+ ~15,000 mn mn mn mn mn bn 2019- 1978-1999 2000-2004 20
Slide 7: Differentiated Pipeline of Complex Generics, Biosimilars
Differentiated Pipeline of Complex Generics, Biosimilars GENERICS APIs Formulations Niche Device Potent Oral Potent APIs Peptide APIs molecules Injectables Topicals Dependent Solids for hospitals Products BIOSIMILARS Commercialized in Human Insulin & Analogs mAbs Fusion proteins Vaccines* Global Mar
Slide 8: Business Segments
cil Business Segments
Slide 9: Our Growth Verticals
Our Growth Verticals Aligned to Global Imperative of Driving Greater Health Equity From pipeline to production, drug discovery to drug delivery, we bring differentiated, high-quality and affordable healthcare products & services globally Ensuring access through A unique, fully integrated Partnering
Slide 10: Our Biosimilars Business
Our Biosimilars Business
Slide 11: Biocon Biologics At A Glance
Biocon Biologics At A Glance 5.5 mn^ 3.75 bn $330+ mn 20 85 Patients served Doses of rh-insulin Private equity Biosimilar molecules Countries where BBL’s through BBL’s supplied to patients investments in portfolio products are available biosimilars globally since 2004 8 3 2 25+ 5,000+ Biosimilars Ma
Slide 12: Biosimilar Value Chain
A Fully Integrated Global Biosimilars Enterprise Emerging Markets Advanced Markets Product Development ✓ ✓ Biosimilar Value Chain Clinical Trials ✓ ✓ Regulatory ✓ ✓ Manufacturing ✓ ✓ Supply Chain ✓ ✓ Commercialization ✓ ✓ ✓ Acquired capabilities post acquisition of Viatris’ biosimilars business
Slide 13: End-to-End Global Scale Capabilities
End-to-End Global Scale Capabilities R&D MANUFACTURING COMMERCIALIZATION ▪ Wide commercial footprint across advanced ▪ Process & Product Development ▪ Mammalian & microbial tech platforms and emerging markets ▪ Analytical & Bioanalytical Capabilities ▪ Manufacturing facilities in India & Malaysia ▪
Slide 14: Comprehensive Portfolio to Address Global Disease Burden
Comprehensive Portfolio to Address Global Disease Burden Today < 2 years 2-4 years >4 years ▪ bPegfilgrastim ▪ bBevacizumab (US) ▪ bAflibercept3 ▪ bPertuzumab ▪ bTrastuzumab ▪ bAspart (US) ▪ bUstekinumab ▪ bGlargine 300 IU ▪ bBevacizumab (EU) ▪ bAdalimumab1 (US) ▪ bDenosumab ▪ Seven undisclosed ▪ bG
Slide 15: Setting New Benchmarks in Biosimilars Globally
Setting New Benchmarks in Biosimilars Globally INSULINS mAbs \ rPROTEINS 2004 2016 2020 2021 2014 2017 2018 World’s 1st 1st company 1st company 1st company bTrastuzumab 1st company 1st company Pichia pastoris- from India to from India to globally to launched in globally to get globally to get techno
Slide 16: Fully Integrated, Global Scale Manufacturing Facilities
Fully Integrated, Global Scale Manufacturing Facilities ▪ Proprietary Pichia pastoris, mammalian CHO & NSO cell-based platforms ▪ Drug Substance, Drug Product & Devices Manufacturing Capabilities for Insulins, mAbs ▪ Ranked among Top 15 Global Biopharma Players in terms of Bio-Manufacturing Capacity
Slide 17: B3: India's First Biopharma Facility Awarded by ISPE
B3: India’s First Biopharma Facility Awarded by ISPE 350K Sqft. facility with 4M safe man hours 3.5x current capacity
Slide 18: Historic Acquisition of Viatris' Global Biosimilars Business
Historic Acquisition of Viatris’ Global Biosimilars Business: November 2022 Provides full Accelerates BBL’s ownership direct entry in of collaboration > USD 3 bn Acquisition - Among many markets assets, as well as across AMs & EMs, Viatris’ rights for Largest Deals in Indian Pharma takes us closer t
Slide 19: Strategic Alliance with SILS for Vaccines
Strategic Alliance with SILS for Vaccines in Infectious Diseases 1 2 3 Access to 100 mn Commercialization Committed doses of vaccines rights of the SILS revenues and annually for 15 portfolio for global related margins years markets from H2 FY23 ~15% stake at a post-money valuation of ~USD 4.9 billi
Slide 20: Branded Formulations: Making Impact in India
Branded Formulations: Making Impact in India Providing World Class Treatment Options Across Therapies; Benefitted 2.5+ Mn Patients’ Lives in India TOUCHED ~1.7 MILLION PATIENT LIVES OVER 25,000 PATIENTS TOUCHED ~18,000 TOUCHED 42,000 LIVES INSUGEN + BASALOG TREATED LIVES Patient numbers as on March
Slide 21: Our Generics Business
BS Biocon (bs Our Generics Business
Slide 22: Generics Business At A Glance
Generics Business At A Glance Presence in 50+ R&D team of 100+ 5 cGMP approvals 300+ countries including State-of-the-art received from scientists U.S., Europe & large facilities international EMs regulatory agencies Supplying to Portfolio comprises 500+ 300+ 1000+ 50+ DMFs filed in various Patents
Slide 23: Growing Portfolio of Active Pharmaceutical Ingredients (APIs)
Growing Portfolio of Active Pharmaceutical Ingredients (APIs) Leadership in fermentation-based APIs 40+ APIs Among world’s largest manufacturers of 700+ API customers statins & immunosuppressant APIs Balanced portfolio: Cardiovascular, anti- 75+ countries served by APIs across US, diabetes, immunosu
Slide 24: Generics Formulations: Vertically Integrated with In-House APIs
Generics Formulations: Vertically Integrated with In-House APIs Products Launched in U.S. Forward integrating portfolio of niche, 1 ▪ Rosuvastatin Calcium difficult-to-make APIs into formulations 2 ▪ Simvastatin Portfolio spans Cardiovascular, 3 ▪ Atorvastatin Metabolics, Oncology, Immunology & Auto
Slide 25: Manufacturing Operations
Manufacturing Operations 5 state-of-the-art facilities in Bengaluru, Hyderabad and Visakhapatnam Technology platforms include microbial fermentation, chromatographic purification, chemical synthesis, peptide synthesis, HPAPIs 2 new facilities – an immunosuppressants plant and a peptides facility – a
Slide 26: Our Novel Biologics Business
Our Novel Biologics Business
Slide 27: Novel Biologics
Novel Biologics Asset Details Disease Area Partnered with Equillium* • Got U.S. FDA’s ‘fast track’ INFLAMMATION designation for aGVHD and (ACUTE GRAFT-VS-HOST Lupus Novel, Humanized • Got U.S. FDA’s ‘orphan DISEASE, LUPUS, ULCERATIVE ITOLIZUMAB CD6 Antibody drug’ label for prevention, COLITIS) Pushi
Slide 28: Our Research Services Business
Our Research Services Business
Slide 29: Syngene at a Glance
Syngene at a Glance 25+ 400+ 5,200+ years of scientific Active clients across Scientists excellence multiple sectors 500 15 2mn sq ft PhDs Collaborations with Top 20 World-class R&D pharmaceutical and manufacturing companies infrastructure
Slide 30: Research Services Business
Research Services Business Partnering to Deliver Innovative Scientific Solutions • Integrated R&D & manufacturing services for small & large molecules, ADCs & oligonucleotides • World-class R&D and manufacturing infrastructure • Audited successfully by US FDA, EMA, AAALAC & major life sciences partn
Slide 31: Financials
$ Biocon S Financials
Slide 32: Biocon Group: Financial Highlights for FY22
Biocon Group: Financial Highlights for FY22 Revenue US$ 1.1 Billion FY 22 FY 21 Revenue +14% ₹8,397Cr ₹7,398Cr Biocon: Business Revenue Mix FY 22 Core EBITDA* +18% ₹2,669Cr ₹2,270Cr % margin 32% 31% 28% EBITDA +14% ₹2,183Cr ₹1,907Cr Generics Biosimilars % margin 26% 26% Biosimilars Research Services
Slide 33: Environment, Social, Governance
Environment, Social, Governance
Slide 34: ESG: Going Beyond Financials to Have a Positive Impact
ESG: Going Beyond Financials to Have a Positive Impact Our ESG Strategy Pillars Improve access to high quality therapeutics to drive ‘Patient Equity’ Build an empowering and inclusive workplace creating ‘People Equity’ Adapting to a sustainable business operations for ‘Environment Equity’ Operate wi
Slide 35: ESG: A Culture of Purpose, Ethics & Equity
ESG: A Culture of Purpose, Ethics & Equity Three key criteria used to assess performance and policies beyond financials Environment: Use of resources and impact on the environment Social: People practices and consideration for the broader community Governance: Rules and principles used to run the or
Slide 36: ESG: Recognitions
ESG: Recognitions Published 1st GRI aligned Featured for 1st time in 2021 Improve score of ‘B’ in Secured ‘Bronze’ place, ESG & BRSR Report for in Emerging Markets Index 2021 in Climate Change & improved score of 52 in FY22 with a score of 45; among Water Security 2021 top 15 in India
Slide 37: Among Top Global Pharma & Biotech Employers
Among Top 10 Global Pharma & Biotech Employers Biocon & Biocon Biologics together feature at No 8. Biocon has been on the Top 20 Global Biotech Employers list since 2012 An innovative Treats Provides 2022 2021 Employer Is socially Has loyal leader in the employees employees with rank rank (global HQ
Slide 38: Corporate Social Responsibility
Corporate Social Responsibility Empowering Communities Biocon Foundation’s Programs Align with Schedule VII CSR Activities as Notified Under Section 135 of the Companies Act 2013 Specialist Camps • NCD Camps Primary • Geriatric Camps Healthcare • Well Baby Camps • Dental Camps eLAJ Smart Clinics: ~7
Slide 39: Adding Value, Enhancing Skills
Adding Value, Enhancing Skills Center of Excellence for Advanced Learning in Applied Biosciences Education Partners: Claremont, California, USA Developing high-end talent for the Biotech sector PROGRAMS • Biocon-KGI Certificate Program in Biosciences • A combination of academic and • BITS Biocon Cer
Slide 40: Thank You
THANK YOU Biocon Biologics Corporate Presentation, Developed by Biocon Group Global Communications Team. Write to us at: [email protected] www.bioconbiologics.com December 2022